Status:
WITHDRAWN
Relapse Prevention Study in Newly Abstinent Smokers
Lead Sponsor:
GlaxoSmithKline
Conditions:
Substance Dependence
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the effect of GSK598809 as compared to placebo in preventing recently-quit smokers from going back to smoking.
Detailed Description
The primary objective of this study is to evaluate the efficacy of GSK598809 compared to placebo for the prevention of relapse to smoking in recently abstinent smokers. Subjects who meet eligibility c...
Eligibility Criteria
Inclusion
- has smoked at least 10 cigarettes a day for at least 2 years
- has had multiple previous attempts to quit smoking and relapsed to smoking.
- generally healthy
Exclusion
- cannot be using smokeless tobacco of any type or has tried to quit with medicine.
- does not abuse alcohol or drugs
- certain emotional problems being treated with medications
- pregnant or breast feeding female
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00793468
Start Date
December 1 2008
End Date
December 1 2008
Last Update
February 15 2016
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
DeLand, Florida, United States, 32720
2
GSK Investigational Site
Pembroke Pines, Florida, United States, 33024
3
GSK Investigational Site
Stockbridge, Georgia, United States, 30281
4
GSK Investigational Site
Overland Park, Kansas, United States, 66211